<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83950">
  <stage>Registered</stage>
  <submitdate>21/05/2009</submitdate>
  <approvaldate>12/06/2009</approvaldate>
  <actrnumber>ACTRN12609000443291</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and Safety Comparison of two different topical gels (one active and one vehicle) in combination with an oral antibiotic in the treatment of Moderate to Severe Acne Vulgaris.</studytitle>
    <scientifictitle>Efficacy and Safety Comparison of Adapalene 0.1%/Benzoyl Peroxide 2.5% gel  associated with  Lymecycline 300mg Capsules versus Adapalene 0.1%/Benzoyl Peroxide 2.5% Vehicle Gel associated with Lymecycline 300mg Capsules in the treatment of Moderate to Severe Acne Vulgaris.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Acne</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1g of Adapalene 0.1%/Benzoyl Peroxide 2.5% gel  will be applied once daily in the evening to the entire face for 12 weeks. One Lymecycline 300mg Capsule will be taken orally in the morning with an adequate amount of fluid for 12 weeks.</interventions>
    <comparator>1g of Adapalene 0.1%/Benzoyl Peroxide 2.5% vehicle gel  will be applied once daily in the evening to the entire face for 12 weeks. One Lymecycline 300mg Capsule will be taken orally in the morning with an adequate amount of fluid for 12 weeks. The control group will apply vehicle gel (control) once daily in the evening to the entire face for 12 weeks and take one Lymecycline 300mg oral capsule once daily in the morning with an adequate amount of fluid for 12 weeks.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy
Non-Inflammatory Lesion (open and closed
comedones) and Inflammatory Lesion (papules,
pustules, nodules/cysts if present) counts on the face
(excluding the nose) at each study visit,
Investigators Global Assessment: severity of acne on
a scale from 0 (Clear) to 5 (Very severe) at each study
visit</outcome>
      <timepoint>Baseline, weeks 2, 4, 8 and 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety
Local tolerability scores - Erythema, Scaling, Dryness,
Stinging/Burning at each study visit,
Recording of Adverse Event(s) at each study visit</outcome>
      <timepoint>Baseline, weeks 2, 4, 8 and 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male or female Subjects of any race, between the age of 12
and 35 years inclusive, with moderate to severe acne
vulgaris, meeting specific inclusion/exclusion criteria.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subjects with more than 3 nodules or cysts on the face
2. Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced
acne, etc.),
3. Female Subjects who are pregnant, nursing or planning a pregnancy during the study,</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/08/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>360</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Galderma Australia Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Suite 4, 13B Narabang Way
Belrose NSW 2085</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Galderma Australia Pty Ltd</fundingname>
      <fundingaddress>Suite 4, 13B Narabang Way
Belrose NSW 2085</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Galderma Research and Development</sponsorname>
      <sponsoraddress>Les Templiers, 2400 Route des Colles, BP87 06902 Sophia Antipolis France</sponsoraddress>
      <sponsorcountry>France</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In an attempt to further improve the management of moderate to severe acne, this study aims to investigate the efficacy and safety of a combination of a topical acne gel and an oral antibiotic.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>3/06/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Elna van der Walt</name>
      <address>Galderma Australia 
13B Narabang way Belrose 2085 NSW</address>
      <phone>+61 2 94790600</phone>
      <fax />
      <email>elna.vanderwalt@galderma.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>George Tiong</name>
      <address>Galderma Australia 
13B Narabang way Belrose 2085 NSW</address>
      <phone>+61 2 94790600</phone>
      <fax />
      <email>george.tiong@galderma.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>